title: AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes.
abstract: Avian H7 is one of several influenza A virus subtypes that have the potential to cause pandemics. Herein we describe preclinical results following administration of an investigational H7N1 inactivated detergent-split virion vaccine adjuvanted with the AS03 Adjuvant System. The adjuvanted H7N1 vaccine was highly immunogenic compared to the non-adjuvanted H7N1 vaccine in unprimed mice with less than 100ng of hemagglutinin antigen per dose. In addition, compared to the non-adjuvanted vaccine, the AS03-adjuvanted H7N1 vaccine also induced robust HI and VN antibody responses that cross-reacted with other H7 subtypes, including recently emerged H7N9 virus. These H7 data from the preclinical mouse model add to the existing H5 data to suggest that AS03 adjuvant technology may be generally effective for formulating antigen-sparing detergent-split virion vaccines against intrinsically sub-immunogenic avian influenza A virus subtypes.
authors.affiliation: GSK Vaccines, Laval, QC, Canada. Electronic address: corey.p.mallett@gsk.com.
authors.forename: Corey P
authors.initials: CP
authors.lastname: Mallett
authors.affiliation: GSK Vaccines, Laval, QC, Canada. Electronic address: edith.r.beaulieu@gsk.com.
authors.forename: Edith
authors.initials: E
authors.lastname: Beaulieu
authors.affiliation: GSK Vaccines, Laval, QC, Canada. Electronic address: marie-helene.a.joly@gsk.com.
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Joly
authors.affiliation: GSK Vaccines, Rixensart, Belgium. Electronic address: benoit.baras@gsk.com.
authors.forename: Benoît
authors.initials: B
authors.lastname: Baras
authors.affiliation: Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: xal0@cdc.gov.
authors.forename: Xiuhua
authors.initials: X
authors.lastname: Lu
authors.affiliation: Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: hdy2@cdc.gov.
authors.forename: Feng
authors.initials: F
authors.lastname: Liu
authors.affiliation: Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: mwl2@cdc.gov.
authors.forename: Min Z
authors.initials: MZ
authors.lastname: Levine
authors.affiliation: Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: jmk9@cdc.gov.
authors.forename: Jacqueline M
authors.initials: JM
authors.lastname: Katz
authors.affiliation: GSK Vaccines, King of Prussia, PA, United States. Electronic address: bruce.2.innis@gsk.com.
authors.forename: Bruce L
authors.initials: BL
authors.lastname: Innis
authors.affiliation: GSK Vaccines, Rixensart, Belgium. Electronic address: sandra.giannini@gsk.com.
authors.forename: Sandra L
authors.initials: SL
authors.lastname: Giannini
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D003429:Cross Reactions; D004338:Drug Combinations; D005260:Female; D006385:Hemagglutination Inhibition Tests; D057916:Influenza A Virus, H7N1 Subtype / Q000276:immunology*; D064766:Influenza A Virus, H7N9 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D008810:Mice, Inbred C57BL; D009500:Neutralization Tests; D011136:Polysorbates / Q000008:administration & dosage*; D013185:Squalene / Q000008:administration & dosage*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology; D024502:alpha-Tocopherol / Q000008:administration & dosage*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D004338:Drug Combinations; D007252:Influenza Vaccines; D011136:Polysorbates; D015164:Vaccines, Inactivated; D013185:Squalene; C550253:AS03 adjuvant; D024502:alpha-Tocopherol
keywords: AS03 Adjuvant System; Avian H7 subtype influenza viruses; H7N1influenza vaccine; Unprimed mouse immunogenicity model